These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

843 related items for PubMed ID: 28870573

  • 21. BAFF Index and CXCL13 levels in the cerebrospinal fluid associate respectively with intrathecal IgG synthesis and cortical atrophy in multiple sclerosis at clinical onset.
    Puthenparampil M, Federle L, Miante S, Zito A, Toffanin E, Ruggero S, Ermani M, Pravato S, Poggiali D, Perini P, Rinaldi F, Gallo P.
    J Neuroinflammation; 2017 Jan 17; 14(1):11. PubMed ID: 28095856
    [Abstract] [Full Text] [Related]

  • 22. Voxel-based assessment of differences in damage and distribution of white matter lesions between patients with primary progressive and relapsing-remitting multiple sclerosis.
    Di Perri C, Battaglini M, Stromillo ML, Bartolozzi ML, Guidi L, Federico A, De Stefano N.
    Arch Neurol; 2008 Feb 17; 65(2):236-43. PubMed ID: 18268194
    [Abstract] [Full Text] [Related]

  • 23. Routine CSF parameters as predictors of disease course in multiple sclerosis: an MSBase cohort study.
    Dekeyser C, Hautekeete M, Cambron M, Van Pesch V, Patti F, Kuhle J, Khoury S, Lechner Scott J, Gerlach O, Lugaresi A, Maimone D, Surcinelli A, Grammond P, Kalincik T, Habek M, Willekens B, Macdonell R, Lalive P, Csepany T, Butzkueven H, Boz C, Tomassini V, Foschi M, Sánchez-Menoyo JL, Altintas A, Mrabet S, Iuliano G, Sa MJ, Alroughani R, Karabudak R, Aguera-Morales E, Gray O, de Gans K, van der Walt A, McCombe PA, Deri N, Garber J, Al-Asmi A, Skibina O, Duquette P, Cartechini E, Spitaleri D, Gouider R, Soysal A, Van Hijfte L, Slee M, Amato MP, Buzzard K, Laureys G.
    J Neurol Neurosurg Psychiatry; 2024 Oct 16; 95(11):1021-1031. PubMed ID: 38569872
    [Abstract] [Full Text] [Related]

  • 24. Multimarker risk stratification approach at multiple sclerosis onset.
    Fernández-Paredes L, Casrouge A, Decalf J, de Andrés C, Villar LM, Pérez de Diego R, Alonso B, Álvarez Cermeño JC, Arroyo R, Tejera-Alhambra M, Navarro J, Oreja-Guevara C, López Trascasa M, Seyfferth A, García Martínez MA, Álvarez Lafuente R, Albert ML, Sánchez-Ramón S.
    Clin Immunol; 2017 Aug 16; 181():43-50. PubMed ID: 28578025
    [Abstract] [Full Text] [Related]

  • 25. Cerebrospinal fluid CXCL13 in multiple sclerosis: a suggestive prognostic marker for the disease course.
    Khademi M, Kockum I, Andersson ML, Iacobaeus E, Brundin L, Sellebjerg F, Hillert J, Piehl F, Olsson T.
    Mult Scler; 2011 Mar 16; 17(3):335-43. PubMed ID: 21135023
    [Abstract] [Full Text] [Related]

  • 26. Progressive multiple sclerosis cerebrospinal fluid induces inflammatory demyelination, axonal loss, and astrogliosis in mice.
    Cristofanilli M, Rosenthal H, Cymring B, Gratch D, Pagano B, Xie B, Sadiq SA.
    Exp Neurol; 2014 Nov 16; 261():620-32. PubMed ID: 25111532
    [Abstract] [Full Text] [Related]

  • 27. The alterations of cerebrospinal fluid TNF-alpha and TGF-beta2 levels in early relapsing-remitting multiple sclerosis.
    Grzegorski T, Iwanowski P, Kozubski W, Losy J.
    Immunol Res; 2022 Oct 16; 70(5):708-713. PubMed ID: 35729473
    [Abstract] [Full Text] [Related]

  • 28. Primary progressive multiple sclerosis diagnostic criteria: a reappraisal.
    Montalban X, Sastre-Garriga J, Filippi M, Khaleeli Z, Téllez N, Vellinga MM, Tur C, Brochet B, Barkhof F, Rovaris M, Miller DH, Polman CH, Rovira A, Thompson AJ.
    Mult Scler; 2009 Dec 16; 15(12):1459-65. PubMed ID: 19995843
    [Abstract] [Full Text] [Related]

  • 29. Soluble TREM-2 in cerebrospinal fluid from patients with multiple sclerosis treated with natalizumab or mitoxantrone.
    Öhrfelt A, Axelsson M, Malmeström C, Novakova L, Heslegrave A, Blennow K, Lycke J, Zetterberg H.
    Mult Scler; 2016 Oct 16; 22(12):1587-1595. PubMed ID: 26754805
    [Abstract] [Full Text] [Related]

  • 30. Intrathecal IgM index correlates with a severe disease course in multiple sclerosis: Clinical and MRI results.
    Ozakbas S, Cinar BP, Özcelik P, Baser H, Kosehasanoğullari G.
    Clin Neurol Neurosurg; 2017 Sep 16; 160():27-29. PubMed ID: 28622533
    [Abstract] [Full Text] [Related]

  • 31. Proteomic pattern analysis discriminates among multiple sclerosis-related disorders.
    Komori M, Matsuyama Y, Nirasawa T, Thiele H, Becker M, Alexandrov T, Saida T, Tanaka M, Matsuo H, Tomimoto H, Takahashi R, Tashiro K, Ikegawa M, Kondo T.
    Ann Neurol; 2012 May 16; 71(5):614-23. PubMed ID: 22522477
    [Abstract] [Full Text] [Related]

  • 32. Identification of biomarkers for diagnosis and progression of MS by MALDI-TOF mass spectrometry.
    Teunissen CE, Koel-Simmelink MJ, Pham TV, Knol JC, Khalil M, Trentini A, Killestein J, Nielsen J, Vrenken H, Popescu V, Dijkstra CD, Jimenez CR.
    Mult Scler; 2011 Jul 16; 17(7):838-50. PubMed ID: 21505015
    [Abstract] [Full Text] [Related]

  • 33. Multiple sclerosis: Identification and clinical evaluation of novel CSF biomarkers.
    Ottervald J, Franzén B, Nilsson K, Andersson LI, Khademi M, Eriksson B, Kjellström S, Marko-Varga G, Végvári A, Harris RA, Laurell T, Miliotis T, Matusevicius D, Salter H, Ferm M, Olsson T.
    J Proteomics; 2010 Apr 18; 73(6):1117-32. PubMed ID: 20093204
    [Abstract] [Full Text] [Related]

  • 34. The effects of intrathecal rituximab on biomarkers in multiple sclerosis.
    Topping J, Dobson R, Lapin S, Maslyanskiy A, Kropshofer H, Leppert D, Giovannoni G, Evdoshenko E.
    Mult Scler Relat Disord; 2016 Mar 18; 6():49-53. PubMed ID: 27063622
    [Abstract] [Full Text] [Related]

  • 35. Oligoclonal bands and cerebrospinal fluid markers in multiple sclerosis: associations with disease course and progression.
    Lourenco P, Shirani A, Saeedi J, Oger J, Schreiber WE, Tremlett H.
    Mult Scler; 2013 Apr 18; 19(5):577-84. PubMed ID: 22961214
    [Abstract] [Full Text] [Related]

  • 36. Cerebrospinal fluid levels of CXCL13 are elevated in neuromyelitis optica.
    Zhong X, Wang H, Dai Y, Wu A, Bao J, Xu W, Cheng C, Lu Z, Qiu W, Hu X.
    J Neuroimmunol; 2011 Dec 15; 240-241():104-8. PubMed ID: 22036953
    [Abstract] [Full Text] [Related]

  • 37. Transglutaminase-6 is an autoantigen in progressive multiple sclerosis and is upregulated in reactive astrocytes.
    Cristofanilli M, Gratch D, Pagano B, McDermott K, Huang J, Jian J, Bates D, Sadiq SA.
    Mult Scler; 2017 Nov 15; 23(13):1707-1715. PubMed ID: 28273770
    [Abstract] [Full Text] [Related]

  • 38. Fatigue scores correlate with other self-assessment data, but not with clinical and biomarker parameters, in CIS and RRMS.
    Håkansson I, Johansson L, Dahle C, Vrethem M, Ernerudh J.
    Mult Scler Relat Disord; 2019 Nov 15; 36():101424. PubMed ID: 31586802
    [Abstract] [Full Text] [Related]

  • 39. Expression of chemokine receptors in the different clinical forms of multiple sclerosis.
    Martínez-Cáceres EM, Espejo C, Brieva L, Pericot I, Tintoré M, Sáez-Torres I, Montalban X.
    Mult Scler; 2002 Oct 15; 8(5):390-5. PubMed ID: 12356205
    [Abstract] [Full Text] [Related]

  • 40. Epstein-Barr virus-specific intrathecal oligoclonal IgG production in relapsing-remitting multiple sclerosis is limited to a subset of patients and is composed of low-affinity antibodies.
    Castellazzi M, Contini C, Tamborino C, Fasolo F, Roversi G, Seraceni S, Rizzo R, Baldi E, Tola MR, Bellini T, Granieri E, Fainardi E.
    J Neuroinflammation; 2014 Nov 13; 11():188. PubMed ID: 25391491
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 43.